Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction

详细信息    查看全文

• 作者：Wei Ren Chen¹ ; Feng Tian¹ ; Yun Dai Chen ; ^{cyundai@vip.163.com" class="auth_mail" title="E-mail the corresponding author} ; Jing Wang ; Jun Jie Yang ; Zhi Feng Wang ; Jin Da Wang ; Qing Xiu Ning
• 关键词：Glucagon-like peptide-1 ; No-reflow ; Acute ST-segment elevation myocardial infarction ; Reperfusion injury ; Percutaneous coronary intervention
• 刊名：International Journal of Cardiology
• 出版年：2016
• 出版时间：1 April 2016
• 年：2016
• 卷：208
• 期：Complete
• 页码：109-114
• 全文大小：405 K

文摘

The ‘no-reflow’ phenomenon after a percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) is a strong predictor of both short- and long-term mortality. Glucagon-like peptide-1 (GLP-1) exerts a cardioprotective effect during ischemia reperfusion injury. We planned to evaluate the effects of liraglutide on myocardial no-reflow after PCI for STEMI.

Methods

A total of 284 patients with STEMI undergoing PCI were enrolled in this study between September 2013 and March 2015. Of these, 210 patients were randomized 1:1 to receive either liraglutide or placebo 30 min before PCI (1.8 mg).

Results

The primary end point, the prevalence of no-reflow, was significantly lower in the liraglutide group than in the control group (5% vs. 15%, P = 0.01). Administration of liraglutide was consistently identified as a significant determinant for no-reflow ratio. There was a significant decrease in serum high-sensitivity C-reactive protein levels at 6-hour reperfusion in the liraglutide group compared to the control group (0.87 ± 0.09 mg/dL vs. 0.96 ± 0.10 mg/dL, P < 0.001). During a 3-month follow-up period, no difference was observed in the incidence of major adverse cardiovascular event.

Conclusions

Liraglutide may be associated with less no-reflow in STEMI, which should be confirmed by larger-scale trials.